Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

Mutations in genes of the RAS-BRAF-MAPK-ERK pathway have not been fully explored in patients with chronic lymphocytic leukemia. We, therefore, analyzed the clinical and biological characteristics of chronic lymphocytic leukemia patients with mutations in this pathway and investigated the in vitro re...

Descripción completa

Detalles Bibliográficos
Autores principales: Giménez, Neus, Martínez-Trillos, Alejandra, Montraveta, Arnau, Lopez-Guerra, Mónica, Rosich, Laia, Nadeu, Ferran, Valero, Juan G., Aymerich, Marta, Magnano, Laura, Rozman, Maria, Matutes, Estella, Delgado, Julio, Baumann, Tycho, Gine, Eva, González, Marcos, Alcoceba, Miguel, Terol, M. José, Navarro, Blanca, Colado, Enrique, Payer, Angel R., Puente, Xose S., López-Otín, Carlos, Lopez-Guillermo, Armando, Campo, Elias, Colomer, Dolors, Villamor, Neus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395334/
https://www.ncbi.nlm.nih.gov/pubmed/30262568
http://dx.doi.org/10.3324/haematol.2018.196931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395334/
https://www.ncbi.nlm.nih.gov/pubmed/30262568
http://dx.doi.org/10.3324/haematol.2018.196931

Ejemplares similares